Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab

Cetuximab and panitumumab, two antibodies targeting the extracellular domain of the epidermal growth factor receptor (EGFR), are of major clinical importance particularly in the treatment of metastatic colorectal cancer. As patients may acquire resistance-mediating mutations within the extracellular...

Full description

Bibliographic Details
Main Authors:	Mareike Voigt, Friederike Braig, Markus Göthel, Alexander Schulte, Katrin Lamszus, Carsten Bokemeyer, Mascha Binder
Format:	Article
Language:	English
Published:	Elsevier 2012-11-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S147655861280114X

Similar Items

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
by: Yifan Xu, et al.
Published: (2018-11-01)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
by: E Allen Sickmier, et al.
Published: (2016-01-01)

Cancer Cells Expressing Oncogenic Rat Sarcoma Show Drug-Addiction Toward Epidermal Growth Factor Receptor Antibodies Mediated by Sustained MAPK Signaling
by: Joseph Tintelnot, et al.
Published: (2020-01-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Evolving role of cetuximab in the treatment of colorectal cancer
by: Gunter Schuch, et al.
Published: (2009-07-01)

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
by: Vicente Alonso, et al.
Published: (2018-07-01)

Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies.
by: Michael Preukschas, et al.
Published: (2012-01-01)

Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report
by: Hitomi Kamo, et al.
Published: (2019-01-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
by: Freeman Daniel J, et al.
Published: (2012-07-01)

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
by: Tapan K Nayak, et al.
Published: (2011-03-01)

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
by: Morrison, J, et al.
Published: (2009)

No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
by: Si-wei Zhou, et al.
Published: (2012-01-01)

Treatment of metastatic colorectal cancer: focus on panitumumab
by: Tay RY, et al.
Published: (2015-06-01)

Vektibiks (panitumumab) – novoe monoklonal'noe antitelok retseptoram epidermal'nogo faktora rosta pri lechenii metastaticheskogo kolorektal'nogo raka
by: A A Tryakin, et al.
Published: (2009-12-01)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
by: Madi, A, et al.
Published: (2017)

Panitumumab-Induced Periorbital Dermatitis: A Case Report
by: Pongbangpho N, et al.
Published: (2024-04-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-01-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-02-01)

Enhanced Antitumor Effects of Epidermal Growth Factor Receptor Targetable Cetuximab-Conjugated Polymeric Micelles for Photodynamic Therapy
by: Ming-Hsiang Chang, et al.
Published: (2018-02-01)

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation
by: Nicola Huxley, et al.
Published: (2017-06-01)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
by: Joseph Tintelnot, et al.
Published: (2022-12-01)

Cancer therapy related cardiac dysfunction as a result of Panitumumab
by: Isabelle Senechal, et al.
Published: (2024-04-01)

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer
by: Pui Lam Yip, et al.
Published: (2023-04-01)

Evaluation of the modulating effect of epidermal growth factor receptor inhibitor cetuximab in carbon-tetrachloride induce hepatic fibrosis in rats
by: Mirza Alimullah, et al.
Published: (2024-07-01)

Molecular dissection of an immunodominant epitope in Kv1.2-exclusive autoimmunity
by: Ivan Talucci, et al.
Published: (2024-04-01)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
by: Smith, C, et al.
Published: (2013)

Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab
by: Zeuli Massimo, et al.
Published: (2010-04-01)

PRIDE syndrome associated with panitumumab treatment – case report and literature review
by: Magalena Pałdyna, et al.
Published: (2023-05-01)

RESULTS OF PANITUMUMAB ADDITION TO CONVERSION THERAPY FOR COLORECTAL CANCER LIVER METASTASES
by: M. I. Sekacheva, et al.
Published: (2015-02-01)

Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma
by: Paulo Ricardo Saquete Martins-Filho, et al.
Published: (2013-01-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope
by: Koki Makabe, et al.
Published: (2021-03-01)

Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma
by: Fertig Elana J, et al.
Published: (2012-05-01)

Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells.
by: Kohei Shigeta, et al.
Published: (2013-01-01)

Dissecting antibodies with regards to linear and conformational epitopes.
by: Björn Forsström, et al.
Published: (2015-01-01)